FOSUN PHARMA announced that its holding subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., recently had the pharmaceutical registration application for citric acid vorasertib capsules accepted by the National Medical Products Administration. This new drug is an oral, potent, highly selective, and entirely new structural innovative small molecule drug intended for the treatment of advanced metastatic solid tumors, including HR+ and HER2-positive advanced breast cancer. By November 2024, the group's cumulative R&D investment in this new drug is approximately 0.574 billion RMB. In 2023, the global sales of CDK4/6 inhibitors were approximately 12.62 billion USD.